Rizhao Brother Pharmaceutical Co., Ltd. was established in April 2018 and is located in Rizhao Economic and Technological Development Zone, Shandong Province. It is a high-tech enterprise specializing in the research and development, production, and sales of biological products and pharmaceutical raw materials. The company has a total investment of 500 million yuan and currently has about 300 employees. It has established a production system that meets GMP standards and has been recognized as a high-tech enterprise and a provincial-level specialized and innovative small and medium-sized enterprise. The company has approximately 260 reaction equipment and can produce 3000 tons of active pharmaceutical ingredients annually. Its products, such as mesalazine, phenylfluorenone, atorvastatin, ticagrelor, etc., are exported to countries and regions in Europe, America, Southeast Asia, and other regions.

The company has 2 technology research and development centers and a strong R&D team, including 5 professors and 8 people with doctoral degrees and 12 patents. The company attaches great importance to collaborative innovation between industry, academia and research, and has established deep cooperative relationships with universities such as Zhejiang University and Zhejiang Agriculture and Forestry University. Among them, Zhejiang University has provided strong technical support for the company in process optimization, greatly shortening the synthesis route of core products compared to traditional processes. Relying on the R&D center of Hangzhou Brother Biotechnology Co., Ltd. and the technical strength from universities such as Zhejiang University and Zhejiang A&F University, the company has formed a unique R&D system that combines biotechnology, enzyme technology, and synthesis technology, and its technical strength is at the leading level in the industry.

In terms of production technology, the company excels in various core drug synthesis technologies such as diazotization reaction, Friedel Crafts reaction, Grignard reaction, and low-temperature reaction. The environmental impact assessment announcement shows that the mesalazine production line has applied the diazotization reaction process; At the same time, the company has also established pharmaceutical workshops that comply with GMP standards and US FDA certification requirements, which can undertake the synthesis needs of various difficult drug intermediates and active pharmaceutical ingredients. In addition, the company vigorously develops a new business model of customized research and development (CDMO) for pharmaceutical contracts, undertakes various CMO/CDMO projects, and is committed to providing one-stop solutions from research and development to production for domestic and foreign pharmaceutical companies, helping customers accelerate the product launch process.

Looking towards the future, Rizhao Brother Pharmaceutical will continue to adhere to the business philosophy of "quality first, customer first", relying on strong industry university research cooperation resources and advanced production processes, continuously improving research and development capabilities and global market competitiveness, and providing high-quality and safe pharmaceutical products for patients worldwide.